Shares of Checkpoint Therapeutics Inc. (CKPT) reached a 52-week high of $4.33 during intraday trading yesterday, as the company gears up for a key regulatory catalyst in the coming weeks.
The company's lead investigational product Cosibelimab, an anti-programmed death ligand-1 ("PD-L1") antibody, is under FDA review, with a decision due on December 28, 2024.
Cosibelimab is proposed for the treatment of adults with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.